Community First Health Centers - Medicare Primary Care in Algonac, MI

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

News Archive

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

Study: Stressful situations at work can have negative impact on cardiovascular system and metabolism

Stressful situations at work can have a negative impact on the cardiovascular system and the metabolism. Stress, which is transmitted by direct and indirect signaling pathways, leads to an inflammatory response in the body, which can trigger cardiovascular diseases, amongst others.

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way.

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

Read more Medical News

› Verified 8 days ago

Clinic/Center in Algonac, MI